GLPwatch

Administration errors of compounded semaglutide reported to a poison control center-Case series.

J Am Pharm Assoc (2003) · 2023

Last updated 2026-05-28

Three cases of adverse reactions were reported after incorrect administration of compounded semaglutide, a GLP-1 drug used for weight loss. Two patients accidentally took 10 times the intended dose, leading to symptoms like nausea, vomiting, and abdominal pain that lasted for days. One patient required medical treatment with fluids and anti-nausea medication. Issues included unclear dosing instructions and the use of syringes not designed for the medication.

AI summary of the abstract below.

JournalJ Am Pharm Assoc (2003), 2023
Citations24
Relative citation ratio3.08
NIH percentile85
Molecules semaglutide

Abstract

BACKGROUND: We aimed to increase pharmacists' and regulatory agencies' awareness of emerging issues regarding current practices of semaglutide use in the community that has led to increased reports of administration errors and adverse drug events to our regional poison control center. CASE SUMMARY: We report 3 cases of adverse drug events after incorrect administration of semaglutide for weight loss obtained from compounding pharmacies and an aesthetic spa. Two patients self-administered 10-fold dosing errors. All patients experienced notable symptoms of nausea, vomiting, and abdominal pain with most symptoms lasting for days. Other symptoms of headache, anorexia, weakness, and fatigue were reported in one patient. One patient sought evaluation at a health care facility and responded well to an antiemetic and intravenous fluids. One patient who received their medication from a compounding pharmacy reported receiving a vial with syringes for self-administration; no pharmacist counseling was provided on proper drug administration. One patient reported dosing in milliliters and units rather than in milligrams. PRACTICE IMPLICATIONS: These 3 semaglutide cases highlight the potential for patient harm given current practices. Vials of compounded semaglutide do not use safety features provided by prefilled manufactured pens and allow for large overdoses (e.g., 10-fold dosing errors). Use of syringes not intended for semaglutide contributes to the variability of dosing units (milliliters, units, milligrams), contributing to patient confusion. To address such issues, we encourage increased vigilance in labeling, dispensing, and counseling practices to ensure patients are confident in administering their medication regardless of the formulation. We additionally encourage boards of pharmacy and other regulatory agencies to promote proper use and dispensing of compounded semaglutide. Such vigilance and promotion could decrease the risk of more severe adverse drug events and avoidable hospital utilization that may arise from dosing errors.

Verbatim abstract via PubMed 37392810 ↗

Related research